In this work, we comprehensively exploited the ESCC CAFs-derived metabolic profiles and aimed at investigating whether CAFs-derived metabolites can be applied as biomarkers to identify the progression of tumor malignancy and how these metabolites change the antitumor effect of FAK inhibitors via the regulation of the intercellular signaling crosstalk between tumor cell and CAFs. The gene discussed is PTK2; the disease is esophageal squamous cell carcinoma.